NORTH CHICAGO, Ill., Sept. 10, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 2015 Morgan Stanley Global Healthcare Conference on Friday, Sept. 18, 2015. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 7:45 a.m. Central time.
NORTH CHICAGO, Ill., Sept. 10, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HUMIRA is now the first and only FDA-approved therapy for adults with HS.
NORTH CHICAGO, Ill., Sept. 9, 2015 /PRNewswire/ -- AbbVie today announced the launch of the voting contest phase of its annual AbbVie CF Scholarship program. The public is encouraged to visit www.AbbVieCFScholarship.com today through September 22, 2015 to help determine who will earn a total of $23,000 to pursue their educational dreams during the 2015-2016 school year.
NORTH CHICAGO, Ill., Aug. 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis. The open-label study evaluated the efficacy and safety of venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche.
NORTH CHICAGO, Ill., July 24, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2015.
NORTH CHICAGO, Ill., July 17, 2015 /PRNewswire/ -- C2N Diagnostics and AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). The companies also have begun a Phase 1 clinical study of C2N-8E12 in patients with PSP.
SUNNYVALE, Calif., July 10, 2015 /PRNewswire/ -- Today AbbVie (NYSE: ABBV) announced the European Commission (EC) granted marketing authorization for IMBRUVICA® (ibrutinib) as the first treatment option available in all 28 member states of the European Union (EU) for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Pharmacyclics LLC, an AbbVie company, received FDA approval for IMBRUVICA, which is also the first and only FDA-approved treatment for WM in the United States, in January 2015.1 The approval of IMBRUVICA to treat patients with WM triggers a $20 million milestone payment from Janssen.
NORTH CHICAGO, Ill., July 2, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2015 financial results on Friday, July 24, 2015, before the market opens.
Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.
Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.
Receive alerts on new stories, articles, and more by subscribing to one or more RSS Feeds.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?
